SOUTH SAN FRANCISCO, California, June 2 (TNSxrep) -- Genentech, a member of Roche Group, issued the following news release on May 31, 2026:

* * *

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions

* Late-breaking Phase II data highlight enicepatide's (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of peo . . .

Click here for more information about our products